Arctic Bioscience – Primary insiders participating in convertible loan facility
Reference is made to the stock exchange release from earlier today, 13th January 2025, regarding new funding, including a convertible loan facility of NOK 15 million.
The following primary insiders, or closely related companies to primary insiders, are a part of the total investor consortium:
- Ronja Capital Investment AS, a company closely related to Board Member Tore Tønseth, NOK 3,0 million
- Vartdal Holding AS, a company closely related to Board Member Jan Endre Vartdal, NOK 1,0 million
- Brødrene Vartdal AS, a company closely related to Board Member Jan Endre Vartdal, NOK 1,0 million
- Ajea Invest AS, a company closely related to Board Member Asbjørn Solevågseide, NOK 0,5 million
- Eros AS, a company closely related to Board Member Per Magne Eggesbø, NOK 0,6 million
- Siglar AS, a company closely related to Chairman of the Board Harald Nordal, NOK 0,15 million
- Clu Invest AS, a company closely related to CEO Christer L. Valderhaug, NOK 0,1 million
- Runhild Gammelsæter, Medical Director, NOK 0,05 million
This information is subject to the disclosure requirements pursuant to Regulation EU 596/2014 (MAR) article 19 and the Norwegian Securities Trading Act § 5-12.
For more information, please contact:
Jone R. Slinning
CFO
Phone: +47 948 75 469
E-mail: jone@arctic-bioscience.com
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds.
The company is developing HRO350 – a novel oral drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile.
Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as well as finished goods under the ROMEGA® brand.
Arctic Bioscience is led by a highly skilled team of talents with diverse and highly relevant background.